$31 million upfront for anti-inflammatory after phase 1 http://www.biospectrumasia.com/biospectrum/news/221289/boehringer-ingelheim-acquires-pharmaxis-anti-inflammatory-drug-candidate/page/1 This payment was for the drug only, not for the company. Further payments will be made based on further success.